Literature DB >> 3000794

Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.

M G Grimaldi.   

Abstract

In 22 patients with rheumatoid arthritis oral ticlopidine 250 mg/day for 18 months induced clinical improvement, confirmed by a significant decrease in the counts of involved joint. A significant decrease was observed in the technetium index (Tc-index) and the erythrocyte sedimentation rate (ESR), and a significant increase occurred in the serum sulphydryl (SH) levels. The long-term changes in serum SH and Tc-index produced by ticlopidine may represent a specific antirheumatic activity of this platelet-inhibiting drug.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3000794     DOI： 10.1007/bf00547416

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  31 in total

1.  Some observations on the blood serotonin levels in rheumatoid arthritis with a study of platelet serotonin absorption.

Authors:  N Crawford
Journal:  Clin Chim Acta       Date:  1969-01       Impact factor: 3.786

2.  Ticlopidine - an antiplatelet drug: effects in human volunteers.

Authors:  J R O'Brien; M D Etherington; R D Shuttleworth
Journal:  Thromb Res       Date:  1978-08       Impact factor: 3.944

3.  Platelet-activating activity in synovial fluids of patients with rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and noninflammatory arthropathies.

Authors:  C Shapleigh; F H Valone; P H Schur; E J Goetzl; K F Austen
Journal:  Arthritis Rheum       Date:  1980-07

4.  Effects of long term administration of ticlopidine on platelet function and hemostatic variables.

Authors:  J Conard; C Lecrubier; P Y Scarabin; M H Horellou; M Samama; M G Bousser
Journal:  Thromb Res       Date:  1980-10-01       Impact factor: 3.944

5.  Polymorphonuclear leucocytes release a factor(s) that induces platelet aggregation and ATP release after interaction with insoluble and surface-fixed immune complexes.

Authors:  G Virella; A Espinoza; H Patrick; J A Colwell
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

6.  Thrombocytosis of active rheumatoid disease.

Authors:  M Farr; D L Scott; T J Constable; R J Hawker; C F Hawkins; J Stuart
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

7.  Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity.

Authors:  J Zeller; E Weissbarth; B Baruth; H Mielke; H Deicher
Journal:  Arthritis Rheum       Date:  1983-04

8.  SOluble and insoluble immune complex-platelet interactions in rheumatoid inflammation.

Authors:  R P Yeatts; R Turner; R Collins; J Kaufmann; H Mashburn
Journal:  Ann Rheum Dis       Date:  1978-10       Impact factor: 19.103

9.  Reducing property of some slow acting antirheumatic drugs.

Authors:  F Huck; R de Médicis; A Lussier; G Dupuis; P Federlin
Journal:  J Rheumatol       Date:  1984-10       Impact factor: 4.666

10.  The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces.

Authors:  W T Kniker; C G Cochrane
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307
View more
  3 in total

1.  Correlation between synovial neopterin and inflammatory activity in rheumatoid arthritis.

Authors:  A Krause; H Protz; K M Goebel
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

Review 2.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

3.  Long-term Treatment with Anti-platelet Agents for Collagen-induced Arthritis Improves Radiological Findings.

Authors:  Chan Kim; Toyou Kim; Jihyung Yoo; Dong-Hyuk Sheen; Sang Kwang Lee; Eun-Hye Choi; Tong Jin Chun; Seong-Wook Kang; Seung-Cheol Shim; Mi-Kyoung Lim
Journal:  Osong Public Health Res Perspect       Date:  2017-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.